The Worldwide Influenza Market
- By 2010, the worldwide influenza market is likely to reach $7.1 billion, with average annual growth estimated at 19.8%.
- The worldwide influenza market is estimated at $2.9 billion in 2005, up from $1.5 billion the previous year.
- The market is estimated to reach $7.1 billion in 2010, an increase of more than $4.2 billion over the forecast period.
- The worldwide therapeutics/vaccines market is likely to reach $6.9 billion in 2010, with average annual growth estimated at 20.8%.
Annually, more than 3.5 million people die of influenza, and with the threat of a pandemic government agencies and disease prevention organizations are devoted to gain control of the situation. Many companies have been asked to assist with the problem and others are furthering their position with backing from government agencies. The next year will continue to display support and funding for many research and development programs, product development and pandemic prevention and/or control.
This new report from BCC Research is designed to be a helpful business tool that will provide thorough evaluation of the market for influenza vaccines, therapeutics, and diagnostics. The geographic scope of this study is worldwide, with emphasis on U.S. data. The report identifies markets in general segments: Vaccines/ Therapeutics and Diagnostics. Each market segment discussion provides detailed information based on product categories, use of products, forecasts, and competitive analysis. Additionally, the study covers some of most significant issues and trends and market factors.
SCOPE OF STUDY
- Provides a thorough evaluation of the market for influenza vaccines, therapeutics, and diagnostics.
- Offers a global analysis, with emphasis on U.S. data, and a five-year forecast period through 2010.
- Identifies markets in general segments: Vaccines/Therapeutics and Diagnostics. Each market segment discussion provides detailed information based on product categories, use of products, forecasts, and competitive analysis.
- Covers some of the most significant issues, trends and market factors.
- Profiles the top companies and major players in the market.
The information for this BCC Research report was obtained through primary and secondary data-collection methods. Primary methods included interviews with key representatives in the industry: product development managers, clinical specialists, government departments, and other key representatives involved in the influenza industry. Secondary methods included published literature, investment reports, company literature, and various business journals that have emphasis on influenza products, technology and related information.
Market data for this report pertains to the worldwide market, with U.S. data included. All information is displayed using U.S. dollars at the manufacturers' level. The base year of the report is 2005, with historical data provided for 2003 and 2004, and forecast data provided through 2010. Historical, base year, and forecast data are provided for each market segment of the report. Average annual growth rates are determined through a complication of data, including past trends, future trends, demographics, incidence, mortality, products in research and development, current product growth, and government intervention and stockpiling trends. Competitor market share estimates are provided for each market segment for the 2005 base year.
Melissa Elder is an experienced healthcare market analyst specializing in prescription and over-the-counter pharmaceuticals and various healthcare-related topics. Ms. Elder has worked in the healthcare field for the past eleven years and has a wide range of experience.